Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Nov;12(11):e175-e177.
doi: 10.1016/j.jtho.2017.06.002. Epub 2017 Jun 10.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy

Deepa Rangachari  1 , Xiuning Le  1 , Meghan Shea  1 , Mark S Huberman  1 , Paul A VanderLaan  2 , Susumu S Kobayashi  1 , Daniel B Costa  3
Affiliations
Case Reports

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy

Deepa Rangachari et al. J Thorac Oncol. 2017 Nov.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Cases with ≥5 years (≥60 months) after initiation of crizotinib in 2 patients with advanced ALK-rearranged lung cancers
A. Case no. 1 with computed tomography (CT) of neck before starting and during year 6 of use of crizotinib. Red circle indicates responsive right supraclavicular lymphadenopathy. B. Case no. 2 with CT of chest before starting and during year 5 of use of crizotinib. Red circles indicate responsive subpectoral lymph nodes.
Figure 2
Figure 2. Use of ALK inhibitors, anti-cancer, and palliative therapies for the first 5 years (60 months) after initiation of crizotinib in 26 patients with advanced ALK-rearranged lung cancers
The type of ALK TKI, chemotherapy, or best supportive care are indicated by different colors. Progressive disease by RECIST is indicated by (P), toxicity to crizotinib by (T), use of radiotherapy by (X), loss of patient follow-up by (L), death by (D) and ongoing therapy/survival by (+).
Figure 3
Figure 3. Progression-free and overall survival of patients with ALK-rearranged lung cancers after initiation of crizotinib
A. Progression-free survival (PFS) curve with median and yearly estimates. B. Overall survival (OS) curve with median and yearly estimates. Data was collected and managed using the REDCap electronic data capture at our institution. Tumor genotype was performed using the ALK fluorescence in situ hybridization (FISH) break-apart probe in diagnostic tumor samples. Response evaluation criteria in solid tumors was utilized when reviewing target/non-target radiographic images. PFS and OS were calculated in months (rounded to the nearest full month) from time of initiation of crizotinib. PFS and OS were explored using the Kaplan–Meier method. Statistical analyses and curves were obtained with the GraphPad Prism 6 software (GraphPad Software, La Jolla, CA).
See this image and copyright information in PMC

References

    1. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703. - PMC - PubMed
    1. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370:1189–97. - PMC - PubMed
    1. Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17:234–42. - PMC - PubMed
    1. Costa DB, Shaw AT, Ou SH, et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. J Clin Oncol. 2015;33:1881–8. - PMC - PubMed
    1. Gainor JF, Tan DS, De PT, et al. Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib. Clin Cancer Res. 2015;21:2745–52. - PMC - PubMed

Publication types